Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | YTHDC1 | Q96MU7 | 5/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30332411 | 1.00 | P2RX7 (0.49) | P2RX7ADORA2AADORA1ADORA2BCDK1 | |
| SCHEMBL5161283 | 0.89 | HDAC1 (0.49) | P2RX7ADORA2ACDK1CCNE1CDK2 | |
| SCHEMBL5161068 | 0.88 | HDAC1 (0.51) | P2RX7ADORA2ACCNE1CDK2CYP1A2 | |
| SCHEMBL29444616 | 0.86 | CDK1 (0.51) | P2RX7ADORA2AADORA1CDK1CCNB1 | |
| SCHEMBL183244 | 0.86 | CDK1 (0.51) | P2RX7ADORA2AADORA1CDK1CCNB1 | |
| SCHEMBL20350686 | 0.84 | CDK1 (0.47) | P2RX7ADORA2AADORA1ADORA2BCDK1 | |
| SCHEMBL3441081 | 0.84 | CDK1 (0.64) | ADORA2AADORA1ADORA2BCDK1CCNB1 | |
| SCHEMBL11961126 | 0.83 | P2RX7 (0.52) | P2RX7ADORA2AADORA1CDK1CDK2 | |
| SCHEMBL183088 | 0.83 | P2RX7 (0.44) | P2RX7ADORA2AADORA2BCDK1HDAC1 | |
| SCHEMBL944935 | 0.83 | P2RX7 (0.46) | P2RX7CDK1HDAC1HDAC2YTHDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116217576-B | Near infrared emission fluorescent molecule based on purine skeleton, and preparation method and application thereof | 四川大学 | 2024-06-14 | — | — | CN | claimed |
| CN-116217576-A | Near infrared emission fluorescent molecule based on purine skeleton, and preparation method and application thereof | 四川大学 | 2023-06-06 | — | — | CN | claimed |
| CN-116217576-B | Near infrared emission fluorescent molecule based on purine skeleton, and preparation method and application thereof | 四川大学 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023140640-A1 | HETEROARYL DERIVATIVE AND USES THEREOF | 한양대학교 산학협력단 | 2023-07-27 | — | — | WO | disclosed |
| CN-116217576-A | Near infrared emission fluorescent molecule based on purine skeleton, and preparation method and application thereof | 四川大学 | 2023-06-06 | — | — | CN | disclosed |
| US-10752629-B2 | Calcium channel agonists | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752629-B2 | Calcium channel agonists | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190084984-A1 | CALCIUM CHANNEL AGONISTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190084984-A1 | CALCIUM CHANNEL AGONISTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-03-21 | — | — | US | disclosed |
| US-10174031-B2 | Calcium channel agonists | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174031-B2 | Calcium channel agonists | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-01-08 | — | — | US | disclosed |
| US-20030149060-A1 | A2A adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003051882-A1 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AVENTISUB II INC. | 2003-06-05 | — | — | US | disclosed |
| US-6479487-B1 | INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS | AVENTIS PHARMACEUTICALS INC. | 2002-11-12 | — | — | US | disclosed |
| US-6413974-B1 | INHIBITORS OF CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; PREVENTING APOPTOSIS IN NEURONAL CELLS; ANTINEOPLASTIC AGENTS; NEURONAL INJURY AND DEGENERATION; CEREBROVASCULAR DISEASE | AVENTIS PHARMACEUTICALS INC. | 2002-07-02 | — | — | US | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| EP-1056745-A2 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043676-A2 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | CDK6, CDK5, CDK2 | P2RX7 1055/4885ADORA2A 171/4885ADORA1 797/4885 |
| US-20190084984-A1 | CALCIUM CHANNEL AGONISTS | CACNA1E, CACNA1C, CACNA1S | P2RX7 303/4885ADORA2A 601/4885ADORA1 381/4885 |
| US-20030149060-A1 | A2A adenosine receptor antagonists | ADORA2A, ADORA2B, ADORA3 | P2RX7 61/4885ADORA2A 1/4885ADORA1 4/4885 |
| US-10174031-B2 | Calcium channel agonists | CACNA1E, CACNA1C, CACNA1S | P2RX7 303/4885ADORA2A 601/4885ADORA1 381/4885 |
| US-10752629-B2 | Calcium channel agonists | CACNA1E, CACNA1C, CACNA1S | P2RX7 303/4885ADORA2A 601/4885ADORA1 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.